These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 8686979)

  • 21. Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer.
    Roach M
    Semin Urol Oncol; 1996 May; 14(2 Suppl 2):32-7; discussion 38. PubMed ID: 8725889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
    Beyer DC; McKeough T; Thomas T
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1299-305. PubMed ID: 15817331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
    Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
    BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy?
    Morris LM; Izard MA; Wan WY
    Brachytherapy; 2015; 14(3):322-8. PubMed ID: 25487524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium.
    Ishiyama H; Kamitani N; Kawamura H; Kato S; Aoki M; Kariya S; Matsumura T; Kaidu M; Yoshida K; Hashimoto Y; Noda Y; Lim KHC; Kawase T; Takahashi T; Inaba K; Kumano M; Yoshikawa N; Yoshioka Y; Nakamura K; Hiratsuka J; Itami J; Hayakawa K
    Brachytherapy; 2017; 16(3):503-510. PubMed ID: 28222973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option.
    Allen GW; Howard AR; Jarrard DF; Ritter MA
    Cancer; 2007 Oct; 110(7):1405-16. PubMed ID: 17685384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controversies in prostate cancer radiotherapy: consensus development.
    Lukka H; Warde P; Pickles T; Morton G; Brundage M; Souhami L;
    Can J Urol; 2001 Aug; 8(4):1314-22. PubMed ID: 11564274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
    D'Amico AV; Saegaert T; Chen MH; Renshaw AA; George D; Oh W; Kantoff PW
    Cancer; 2002 Jul; 95(2):275-80. PubMed ID: 12124826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
    Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
    Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
    Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant androgen ablation in localized carcinoma of the prostate.
    Kish JA
    Cancer Control; 2001; 8(2):155-62. PubMed ID: 11326170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in the treatment of prostate cancer.
    Kuyu H; Lee WR; Bare R; Hall MC; Torti FM
    Ann Oncol; 1999 Aug; 10(8):891-8. PubMed ID: 10509148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated?
    Scolieri MJ; Altman A; Resnick MI
    J Urol; 2000 Nov; 164(5):1465-72. PubMed ID: 11025684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202.
    Mirhadi AJ; Zhang Q; Hanks GE; Lepor H; Grignon DJ; Peters CA; Rosenthal SA; Zeitzer K; Radwan JS; Lawton C; Parliament MB; Reznik RS; Sandler HM
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):511-515. PubMed ID: 28126300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management strategies for locally advanced prostate cancer.
    Jani AB
    Drugs Aging; 2006; 23(2):119-29. PubMed ID: 16536635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Locally advanced prostate cancer: effective treatments, but many adverse effects.
    Prescrire Int; 2013 Jan; 22(134):18-20, 22-3. PubMed ID: 23367679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcomes of dynamic conformal arc irradiation combined with neoadjuvant hormonal therapy in Japanese patients with T1c-T2N0M0 prostate cancer: case series study.
    Ikeda I; Mizowaki T; Norihisa Y; Takayama K; Kamba T; Inoue T; Nakamura E; Kamoto T; Ogawa O; Hiraoka M
    Jpn J Clin Oncol; 2014 Feb; 44(2):180-5. PubMed ID: 24379210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer: a matched subset analysis.
    Sylvester J; Blasko JC; Grimm PD; Meier R; Cavanagh W
    Mol Urol; 2000; 4(3):155-9;discussion 161. PubMed ID: 11062369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.